Pharmacokinetics of cysteamine bitartrate following intraduodenal delivery

Fundamental and Clinical Pharmacology

Volumn 28, Issue 2, 2014, Pages 136-143

  Dohil, Ranjan ^a,b   Cabrera, Betty L ^a,b   Gangoiti, Jon A ^a,b   Barshop, Bruce A ^a,b   Rioux, Patrice ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c Raptor Pharmaceutical Corporation   (United States)

Author keywords

Bioavailability; Biodistribution; Cerebrospinal fluid and tissue cystine levels; Cystinosis; Intraduodenal; Tissue

Indexed keywords

MERCAPTAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CYSTINOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG KIDNEY LEVEL; DRUG LIVER LEVEL; DRUG MUSCLE LEVEL; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FIRST PASS EFFECT; GASTROINTESTINAL SYMPTOM; HUNTINGTON CHOREA; JUGULAR VEIN; MALE; MAXIMUM PLASMA CONCENTRATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

BIOAVAILABILITY; BIODISTRIBUTION; CEREBROSPINAL FLUID AND TISSUE CYSTINE LEVELS; CYSTINOSIS; INTRADUODENAL; TISSUE;

ANIMALS; BIOLOGICAL AVAILABILITY; CATHETERS, INDWELLING; CYSTEAMINE; DUODENUM; INTESTINAL ABSORPTION; KIDNEY; LIVER; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84895527965     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12009     Document Type: Article

References (31)

1. Gahl W.A., Thoene J.G., Schneider J.A. Cystinosis. N. Engl. J. Med. (2002) 347 111-121.
2. Gahl W.A., Reed G.F., Thoene J.G. et al. Cysteamine therapy for children with nephropathic cystinosis. N. Engl. J. Med. (1987) 316 971-977.
3. Markello T.C., Bernardini I.M., Gahl W.A. Improved renal function in children with cystinosis treated with cysteamine. N. Engl. J. Med. (1993) 328 1157-1162.
4. Kleta R., Bernardini I., Ueda M. et al. Long-term follow-up of well-treated nephropathic cystinosis patients. J. Pediatr. (2004) 145 555-560.
5. Dohil R., Schmeltzer S., Cabrera B.L. et al. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. (2011) 33 1036-1044.
6. Dedeoglu A., Kubilus J.K., Jeitner T.M. et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. (2002) 22 8942-8950.
7. Lesort M., Lee M., Tucholski J., Johnson G.V. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. (2003) 278 3825-3830.
8. Kessler A., Biasibetti M., da Silva Melo D.A. et al. Antioxidant effect of cysteamine in brain cortex of young rats. Neurochem. Res. (2008) 33 737-744.
9. Kessler A., Biasibetti M., Feksa L.R. et al. Effects of cysteamine on oxidative status in cerebral cortex of rats. Metab. Brain Dis. (2008) 23 81-93.
10. Maher P., Lewerenz J., Lozano C., Torres J.L. A novel approach to enhancing cellular glutathione levels. J. Neurochem. (2008) 107 690-700.
11. Wood P.L., Khan M.A., Moskal J.R. Cellular thiol pools are responsible for sequestration of cytotoxic reactive aldehydes: central role of free cysteine and cysteamine. Brain Res. (2007) 1158 158-163.
12. Lorand L. DRPLA aggregation and transglutaminase, revisited. Nat. Genet. (1998) 20 231.
13. Jeitner T.M., Delikatny E.J., Ahlqvist J., Capper H., Cooper A.J. Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem. Pharmacol. (2005) 69 961-970.
14. Hoffner G., Andre W., Vanhoutteghem A., Soues S., Djian P. Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition. CNS Neurol. Disord. Drug. Targets (2010) 9 217-231.
15. Dohil R., Fidler M., Barshop B.A. et al. Understanding intestinal cysteamine bitartrate absorption. J. Pediatr. (2006) 148 764-769.
16. Dohil R., Fidler M., Gangoiti J.A., Kaskel F., Schneider J.A., Barshop B.A. Twice-daily cysteamine bitartrate therapy for children with cystinosis. J. Pediatr. (2010) 156 71-75.
17. Dohil R., Gangoiti J.A., Cabrera B.L., Fidler M., Schneider J.A., Barshop B.A. Long-term treatment of cystinosis in children with twice-daily cysteamine. J. Pediatr. (2010) 156 823-827.
18. Langman C.B., Greenbaum L.A., Sarwar M. et al. A randomized controlled crossover trial with RP103 for nephropathic cystinosis. Clin. J. Am. Soc. Nephrol. (2012) 7 112-120
19. Lichtenberger L.M., Szabo S., Reynolds E.S. Gastric emptying in the rat is inhibited by the duodenal ulcerogens, cysteamine and propionitrile. Gastroenterology (1977) 73 1072-1076.
20. Fidler M.C., Barshop B.A., Gangoiti J.A. et al. Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion. Br. J. Clin. Pharmacol. (2007) 63 36-40.
21. Szabo S. Duodenal ulcer disease. Animal model: cysteamine-induced acute and chronic duodenal ulcer in the rat. Am. J. Pathol. (1978) 93 273-276.
22. Belldina E.B., Huang M.Y., Schneider J.A., Brundage R.C., Tracy T.S. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. Br. J. Clin. Pharmacol. (2003) 56 520-525.
23. Eldjarn L., Nygaard O. Cysteamine-cystamine: intestinal absorption, distribution among various organs and excretion. Arch. Int. Physiol. Biochim. (1954) 62 476-486.
24. Sonies B.C., Almajid P., Kleta R., Bernardini I., Gahl W.A. Swallowing dysfunction in 101 patients with nephropathic cystinosis: benefit of long-term cysteamine therapy. Medicine (Baltimore) (2005) 84 137-146.
25. Khomenko T., Kolodney J., Pinto J.T. et al. New mechanistic explanation for the localization of ulcers in the rat duodenum: role of iron and selective uptake of cysteamine. Arch. Biochem. Biophys. (2012) 55 60-70
26. Levtchenko E.N., de Graaf-Hess A., Blom H.J., Monnens L.A. Negligible urinary cysteamine loss in cystinosis patients with Fanconi syndrome. Clin. Nephrol. (2002) 57 349-351.
27. Dohil R., Carrigg A., Newbury R. A potential new method to estimate tissue cystine content in nephropathic cystinosis. J. Pediatr. (2012) 161 531-535.
28. Kaiser-Kupfer M.I., Fujikawa L., Kuwabara T., Jain S., Gahl W.A. Removal of corneal crystals by topical cysteamine in nephropathic cystinosis. N. Engl. J. Med. (1987) 316 775-779.
29. Park M., Helip-Wooley A., Thoene J. Lysosomal cystine storage augments apoptosis in cultured human fibroblasts and renal tubular epithelial cells. J. Am. Soc. Nephrol. (2002) 13 2878-2887.
30. Sanyal A.J., Campbell-Sargent C., Mirshahi F. et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 120 1183-1192.
31. Gangoiti J.A., Fidler M., Cabrera B.L., Schneider J.A., Barshop B.A., Dohil R. Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: a pilot study. Br. J. Clin. Pharmacol. (2010) 70 376-382.